AQP4+NMOSD (n=27) | RRMS (n=45) | p value | |
ΔEDSS (MRI-2 – MRI-1) | 0.0 (0.0) (–2.0–0.5) | 0.0 (0.0) (–3.0–1.0) | 0.83 |
Years from MRI-1 to MRI-2 | 3.0 (2.3) (1.0–6.3) | 2.0 (1.8) (1.0–5.1) | 0.12 |
At MRI-1 | |||
ICV*10-3 (mL) | 1.3 (0.12) (1.2–1.5) | 1.4 (0.13) (1.2–1.7) | 0.018* |
NLV (mL) | 0.96 (4.5) (0.0–33.2) | 7.1 (12.9) (0.45–46.7) | <0.001* |
NGV*10-3 (mL) | 0.44 (0.047) (0.32–0.49) | 0.44 (0.067) (0.32–0.50) | 0.97 |
NWV*10-3 (mL) | 0.31 (0.029) (0.24–0.33) | 0.29 (0.028) (0.25–0.33) | 0.001* |
NBV*10-3 (mL) | 0.75 (0.077) (0.62–0.81) | 0.72 (0.086) (0.59–0.80) | 0.19 |
At MRI-2 | |||
ICV*10-3 (mL) | 1.3 (0.12) (1.2–1.5) | 1.4 (0.14) (1.2–1.7) | 0.056 |
NLV (mL) | 1.7 (8.7) (0.0–141) | 8.0 (11.8) (0.0–187) | 0.026* |
NGV*10-3 (mL) | 0.43 (0.061) (0.31–0.49) | 0.42 (0.063) (0.33–0.50) | 0.95 |
NWV*10-3 (mL) | 0.31 (0.028) (0.22–0.34) | 0.29 (0.028) (0.24–0.38) | 0.001* |
NBV*10-3 (mL) | 0.75 (0.078) (0.60–0.80) | 0.71 (0.094) (0.58–0.80) | 0.21 |
Annualised atrophy rate | |||
NGV (%) | 0.69 (1.2) (–1.7–3.0) | 0.60 (1.7) (–2.5–4.5) | 0.69 |
NWV (%) | 0.16 (1.2) (–0.62–1.1) | 0.19 (1.9) (–3.2–6.3) | 0.81 |
NBV (%) | 0.50 (0.75) (–0.20–0.77) | 0.42 (0.85) (–1.3–3.4) | 0.73 |
Data are presented as median number (%) or (IQR) (range). *p<0.05.
Annualised atrophy rate of X is defined as follows: , X= NGV, NWV or NBV.
ΔEDSS=EDSS at MRI-2 minus EDSS at MRI-1.
AQP4+NMOSD, anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder disease; EDSS, Kurtzke’s Expanded Disability Status Scale; ICV, intracranial volume; NBV, normalised brain volume; NGV, normalised grey matter volume; NLV, normalised lesion volume; NWV, normalised white matter volume.